SPP1 and metabolic dysfunction-associated steatotic liver disease: A recent study in a murine NASH model demonstrated that antibodies targeting OPN not only attenuated fibrosis but also inflammation, suggesting that targeting OPN in the early stages of NAFLD may be effective in preventing the progression to NASH and fibrosis [21].